Cargando…

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function

This review aims to examine the complex interaction between dyslipidemia, platelet function, and related drug treatments. In particular, the manuscript provides an overview of the effects of major hypolipidemic drugs on platelet function. Indeed, growing evidence supports the view that statins, ezet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Costanzo, Assunta, Indolfi, Ciro, Sorrentino, Sabato, Esposito, Giovanni, Spaccarotella, Carmen Anna Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380733/ https://www.ncbi.nlm.nih.gov/pubmed/37511498 http://dx.doi.org/10.3390/ijms241411739

Ejemplares similares

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
por: Choi, Jah Yeon, et al.
Publicado: (2019)

Reduction of hospitalisations and increased mortality for acute coronary syndromes during covid-19 era: Not all countries are equal
por: Spaccarotella, Carmen, et al.
Publicado: (2021)

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
por: Kong, Ni, et al.
Publicado: (2022)

Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment
por: Weintraub, William S., et al.
Publicado: (2022)

Lp(a) in the Pathogenesis of Aortic Stenosis and Approach to Therapy with Antisense Oligonucleotides or Short Interfering RNA
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

Icosapent ethyl for the treatment of severe hypertriglyceridemia
por: Fares, Hassan, et al.
Publicado: (2014)

Icosapent ethyl: scientific and legal controversies
por: Curfman, Gregory, et al.
Publicado: (2021)

Clinical results and mechanism of action of icosapent ethyl
por: Borghi, Claudio, et al.
Publicado: (2023)

Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence
por: Condello, Francesco, et al.
Publicado: (2023)

To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy
por: Spaccarotella, Carmen, et al.
Publicado: (2023)

Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary
por: Vohra, Laiba Imran, et al.
Publicado: (2023)

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
por: Parhofer, Klaus G, et al.
Publicado: (2020)

Icosapent Ethyl (Vascepa®) for the Treatment of Acute, Severe Pancreatitis
por: Berger, Amnon A, et al.
Publicado: (2020)

Statin and Ezetimibe Combination Therapy Decreases Mean Platelet Volume Compared to Statin Monotherapy
por: Lee, Jun-beom, et al.
Publicado: (2017)

Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
por: Merćep, Iveta, et al.
Publicado: (2022)

Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients for the Treatment of Severe Aortic Stenosis
por: Polimeni, Alberto, et al.
Publicado: (2020)

Common Calcified Femoral Artery Rupture After Intravascular Lithotripsy for TAVR Implantation
por: Spaccarotella, Carmen, et al.
Publicado: (2020)

Effect of Concomitant Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on the Pharmacokinetics of Atorvastatin
por: Braeckman, Rene A., et al.
Publicado: (2014)

Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis
por: Brinton, Eliot A., et al.
Publicado: (2018)

Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
por: Budoff, Matthew J, et al.
Publicado: (2020)

Potential Benefits of Icosapent Ethyl on the Lipid Profile: Case Studies
por: Hilleman, Daniel E., et al.
Publicado: (2014)

Beyond cardiovascular medicine: potential future uses of icosapent ethyl
por: Bhatt, Deepak L, et al.
Publicado: (2020)

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
por: Jia, Xiaoming, et al.
Publicado: (2020)

The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk
por: Khan, Muhammad Shoaib, et al.
Publicado: (2021)

A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction
por: Huston, Jessica, et al.
Publicado: (2023)

PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection
por: Arnold, Natalie, et al.
Publicado: (2022)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
por: Wang, Shuai, et al.
Publicado: (2022)

Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms
por: Xu, Rui-Xia, et al.
Publicado: (2015)

Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series
por: Castaldo, Richard S.
Publicado: (2016)

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study
por: Ballantyne, Christie M., et al.
Publicado: (2019)

Clinical and Procedural Outcomes of 5-French versus 6-French Sheaths in Transradial Coronary Interventions
por: Polimeni, Alberto, et al.
Publicado: (2015)

Differences in coagulopathy indices in patients with severe versus non-severe COVID-19: a meta-analysis of 35 studies and 6427 patients
por: Polimeni, Alberto, et al.
Publicado: (2021)

The Outbreak of COVID-19 in Italy: Fighting the Pandemic
por: Indolfi, Ciro, et al.
Publicado: (2020)

Icosapent Ethyl – A Successful Treatment for Symptomatic COVID-19 Infection
por: Berger, Amnon A, et al.
Publicado: (2020)

Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside
por: Bhatt, Deepak L
Publicado: (2020)

Cardiovascular Risk Reduction With Icosapent Ethyl: A Systematic Literature Review
por: Thakur, Mala, et al.
Publicado: (2020)

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
por: Peterson, Benjamin E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_onv2nk9520rot2po8tr705q9g0